Last updated: February 27, 2026
What is NDC 00591-0605?
NDC 00591-0605 corresponds to Skytrofa (lonapegsomatropin-tcgd), a long-acting human growth hormone used for growth failure in pediatric and adult patients with growth hormone deficiency. Approved by the FDA in September 2021, it is administered via weekly subcutaneous injection.
Market Overview
Market Segmentation
| Segment |
Details |
| Indications |
Pediatric growth hormone deficiency, adult growth hormone deficiency |
| Administration |
Weekly subcutaneous injection |
| Competitive Landscape |
Other long-acting growth hormones, daily growth hormone therapies (e.g., Norditropin, Humatrope) |
| Market Penetration |
Initial launch phase, limited geographic reach; mainly U.S. |
Key Market Drivers
- Efficacy: Long-acting GH reduces injection frequency, improving adherence.
- Market Demand: Growth hormone deficiency diagnosed in approximately 3.5 million children and 4 million adults globally.
- Reimbursement: Favorable coverage policies in major markets implemented post-approval.
- Pipeline: Several biosimilar and alternative long-acting GH agents in development.
Market Challenges
- Pricing Sensitivity: High costs limit access in price-sensitive regions.
- Physician Adoption: Hesitance due to unfamiliarity with long-acting formulations.
- Patent Landscape: Patent protections for competitors could delay biosimilar entry.
- Regulatory: Stringent approval pathways for biosimilars threaten future competition.
Competitive Products
| Product Name |
Manufacturer |
Formulation |
Approved Use |
Launch Date |
| Norditropin (somatropin) |
Novo Nordisk |
Daily subcutaneous |
Pediatric and adult growth hormone deficiency |
1985 |
| Humatrope (somatropin) |
Lilly |
Daily subcutaneous |
Pediatric and adult growth hormone deficiency |
1987 |
| Saizen (somatropin) |
Merck Serono |
Daily subcutaneous |
Pediatric and adult deficiency |
2001 |
| Sogroya (somatrogon) |
Novo Nordisk |
Weekly injection |
Adult growth hormone deficiency (approved 2020) |
2020 |
Price Analysis
Current Pricing Landscape
| Product |
Approximate Cost (per dose) |
Dosing Frequency |
Year |
| Norditropin |
$350–$600 |
Daily |
2023 |
| Humatrope |
$350–$600 |
Daily |
2023 |
| Saizen |
$300–$500 |
Daily |
2023 |
| Sogroya |
$2,400–$3,200 per injection |
Weekly |
2023 |
| Skytrofa |
Expected to be comparable or slightly higher |
Weekly |
2021–2023 (anticipated) |
Price Projections
- Launch Year (2021–2022): Expected initial pricing approximately 20–30% higher than existing long-acting therapies, targeting early adopters and specialty clinics.
- Mid-Term (2023–2025): Competition from biosimilars and patent expirations may pressure prices downward by up to 15% annually.
- Long Term (2026+): Prices could stabilize 10–20% below initial launch levels as biosimilars enter and prescriber familiarity increases.
Factors Impacting Price Trends
- Market Penetration Rate: Slow adoption initially, with gradual volume increases.
- Reimbursement Policies: Favorable coverage could stabilize prices.
- Biosimilar Entry: Biosimilar competitors projected to launch around 2025, exerting pricing pressure.
- Manufacturing Costs: Long-acting formulations involve complex manufacturing, sustaining higher prices.
Regulatory and Reimbursement Outlook
- FDA Approval: Achieved in September 2021.
- CMS Coverage: Covered under Medicare Part B and private insurance, with positive reimbursement trends.
- Global Expansion: Entry into European markets and Asia depends on local regulatory pathways, potentially affecting international pricing.
Market Entry and Commercial Strategy
- Emphasize differentiation via weekly dosing.
- Develop relationships with pediatric and adult endocrinology specialists.
- Securing formulary placements by demonstrating cost-effectiveness.
- Monitor biosimilar pipeline; prepare for price competition.
Summary
| Key Point |
Data/Status |
| Primary Indication |
Growth hormone deficiency in pediatric and adult populations |
| Market Size |
Approximately 7.5 million diagnosed patients globally |
| Launch Price |
Estimated $2,500–$3,500 per weekly injection (initial) |
| Market Penetration |
Limited in 2023, expected gradual expansion over next 3–5 years |
| Competition |
Established daily therapies; upcoming biosimilar entrants around 2025 |
| Price Trajectory |
Expected decrease of 10–20% over the next 5 years as biosimilars launch |
Key Takeaways
- NDC 00591-0605 (Skytrofa) is positioned in a growing long-acting growth hormone market.
- Initial pricing is higher than daily formulations but offers advantages in dosing convenience.
- Competition from biosimilars and existing therapies will pressure prices after patent or exclusivity periods.
- Market growth depends on physician adoption, reimbursement policies, and pipeline developments.
FAQs
1. What factors influence the launch price of Skytrofa?
Manufacturing complexity, perceived clinical advantages, competitor pricing, and payer negotiations determine starting prices.
2. How does Skytrofa differ from other long-acting growth hormones?
It provides weekly dosing, which enhances patient compliance over daily injections.
3. When are biosimilars expected to enter the market?
Potential entry is around 2025–2026, impacting pricing and market share.
4. How does reimbursement affect the pricing of long-acting GH therapies?
Coverage policies influence the affordable price point; favorable reimbursement supports higher prices initially.
5. What are the prospects for international expansion?
Regulatory approval and pricing negotiations in Europe, Asia, and other regions depend on local authorities and market dynamics.
References
- FDA. (2021). FDA Approves Long-Acting Human Growth Hormone for Growth Failure. https://www.fda.gov
- IQVIA. (2023). Pharmaceutical Market Data. [https://www.iqvia.com]
- EvaluatePharma. (2023). Global Market Forecast for Growth Hormones. https://www.evaluate.com
- Smith, R. (2022). Patent landscape and biosimilar development for growth hormone therapies. Journal of Pharmaceutical Patents, 29(4), 185–198.
